ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)

44

BURLINGTON, Mass.–(BUSINESS WIRE)–$ARQL #arql–ArQule, Inc. (Nasdaq: ARQL), today announced that it will present clinical data from the company-sponsored phase 1 dose escalation study on its BTK inhibitor, ARQ 531, for the treatment of relapsed or refractory B-cell lymphoid malignancies in a poster presentation at the 24th Congress of European Hematology Association (EHA), held from June 13-16, 2019 in Amsterdam. Presentation Details Title: A Phase 1 Dose Escalation Study Of ARQ 531 In Patients with Relap…..

 

http://www.businesswire.com/news/home/20190607005029/en/ArQule-Present-Clinical-Data-BTK-Inhibitor-ARQ